hCCR8

Fig1. Overall proportions of immune cells in the blood of humanized CCR8 mouse.

Fig2. Overall proportions of immune cells in the spleen of humanized CCR8 mouse.

Fig3. hCCR8 expression validation in humanized CCR8 mouse.

Fig4. Binding of anti-hCCR8 to spleen-derived T cells in humanized CCR8 mouse.

Fig 5. In vivo efficacy study in CCR8 humanized mice grafted with MC38-OVA syngeneic tumor model.

Human specific anti-CCR8 retards the MC38-OVA  tumor growth in vivo and leads to the depletion of tumor-resident CCR8+ Treg cells. (A) Schematic diagram of dosing  regimen; (B) Mean tumor volumes and individual tumor volumes; (C) Tumor infiltrating CCR8+ Tregs post treatment (Teal column, vehicle control; Yellow column, anti-hCCR8). (In collaboration with Crownbio)

Fig 6.   In vivo efficacy study in CCR8 humanized mice grafted with Hepa1-6 syngeneic tumor model. 

Human specific anti-CCR8 retards the Hepa1-6  tumor growth in vivo and leads to the depletion of tumor-resident CCR8+ Treg cells.(A) Schematic diagram of dosing regimen; (B) Mean tumor volumes and individual tumor volumes; (C) Tumor infiltrating CCR8+Tregs post treatment (Teal column, vehicle control; Yellow column, anti-hCCR8).(In collaboration with Crownbio)